GT Biopharma (NASDAQ:GTBP) Downgraded to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of GT Biopharma (NASDAQ:GTBP) to a strong sell rating in a report issued on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of GT Biopharma in a report on Wednesday, July 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

GT Biopharma Price Performance

GT Biopharma stock opened at $8.61 on Friday. The business has a 50 day moving average of $8.02 and a 200-day moving average of $9.67. The company has a market capitalization of $15.50 million, a P/E ratio of -0.06 and a beta of 0.91. GT Biopharma has a 1 year low of $4.91 and a 1 year high of $34.25.

GT Biopharma (NASDAQ:GTBP) last posted its earnings results on Friday, August 14th. The company reported ($3.00) EPS for the quarter, missing the consensus estimate of ($2.00) by ($1.00). Equities analysts anticipate that GT Biopharma will post -10.75 EPS for the current year.

Hedge Funds Weigh In On GT Biopharma

An institutional investor recently bought a new position in GT Biopharma stock. 49 Wealth Management LLC acquired a new position in GT Biopharma, Inc. (NASDAQ:GTBP) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 64,000 shares of the company’s stock, valued at approximately $31,000. 49 Wealth Management LLC owned 0.14% of GT Biopharma at the end of the most recent reporting period. 8.15% of the stock is currently owned by hedge funds and other institutional investors.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).